Random

Ozempic

This shows a person running and a brain.

·June 13, 2026·8 min read

GLP-1 Therapies Silence Spontaneous Physical Activity

A new study demonstrates that adults managing obesity significantly decrease their physical activity after starting GLP-1 receptor agonist medications.

Featured Neuroscience Psychology

·July 29, 2026·8 min read

Oral Ozempic Cuts Heavy Drinking and Cravings

Oral semaglutide reduces heavy drinking days, daily cravings, and alcohol-related problems in adults with Alcohol Use Disorder.

This shows a brain made of gut bacteria.

Featured Neuroscience Psychology

·June 10, 2026·9 min read

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

The GLP-1 agonist liraglutide treats depressive symptoms via a novel microbial pathway.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

Featured Neuroscience Psychology

·July 16, 2026·13 min read

GLP-1’s Reduce Binge Eating Symptoms

A new study establishes that GLP-1 receptor agonists significantly reduce core behavioral markers of Binge Eating Disorder, including active binge episodes, loss-of-control eating, and emotional eating.

This shows an older man and a brain scan.

Featured Neurology Neuroscience

·June 21, 2024·4 min read

Ozempic May Reduce Alzheimer’s Risk

GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.

Featured Genetics Neuroscience

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

Featured Neuroscience Psychology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

Featured Neuroscience Visual Neuroscience

·July 3, 2024·7 min read

Ozempic Linked to Increased Risk of Blinding Eye Condition

A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, a potentially blinding eye condition. Diabetic patients on semaglutide were over four times more likely to be diagnosed with NAION, while overweight patients were over seven times more likely. The findings suggest the need for careful discussions between patients and doctors about this risk. NAION remains a rare but serious condition with no effective treatments.